Gaps in US Psychedelic Policy and How to Close Them
Caleigh Propes, Katherine Cheung, Matthew D. Eisenberg, David B. Yaden
JAMA Health Forum November 7, 2025 DOI: 10.1001/jamahealthforum.2025.4928 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Addiction |
| Keywords | Mental health Government linguistics Public policy Action physics Substance use Criminology Public relations |
| Citations | 4 |
| Key points | Policy gaps surrounding the use of psychedelics for mental health and substance use conditions need to be addressed before and after potential FDA approval. |
Abstract
This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.
Citations in the library
Cited by 6
- Systems-based psychiatry: insights from psychedelic research on mechanisms of healing Frontiers in Psychiatry July 13, 2026
- Balancing safety and access in Oregon’s psilocybin services International Journal of Drug Policy June 13, 2026
- Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland. The International Journal of Neuropsychopharmacology June 2, 2026
- Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence Exploratory Research in Clinical and Social Pharmacy February 4, 2026
- Ethics of psychedelics in clinical research: a state-of-the-field review JME Practical Bioethics October 9, 2026
and 1 more in the library
Cites 5
- Transformative experience and informed consent to psychedelic-assisted psychotherapy Frontiers in Psychology May 26, 2023
- The varieties of psychedelic law Neuropharmacology December 21, 2022
- Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines Neuropharmacology August 13, 2022
- Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial PLoS One February 25, 2022
- Psychedelic and MDMA-Related Adverse Effects-A Call for Action. JAMA Health Forum November 1, 2024